Monotropein inhibits colitis associated cancer through VDR/JAK1/STAT1 regulation of macrophage polarization

Yingyu Lu1, Yonger Chen1, Yuhua Li1

  • 1School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, PR China.

PubMed

Insights

Monotropein, derived from Morinda officinalis, combats colitis-associated cancer by targeting the VDR/JAK1/STAT1 pathway. This natural compound promotes M1 macrophage polarization, reducing tumor progression and offering a less toxic therapeutic avenue for colorectal cancer (CRC).

Area of Science:

  • Pharmacology and Molecular Biology
  • Cancer Research
  • Immunology

Background:

  • Colorectal cancer (CRC) presents significant morbidity and mortality challenges.
  • Investigating novel, less toxic therapeutic agents for CRC and inflammatory bowel diseases is crucial.
  • Monotropein, from Morinda officinalis, shows potential but requires mechanism elucidation for CRC treatment.

Purpose of the Study:

  • To determine if monotropein targets Vitamin D Receptor (VDR) proteins.
  • To investigate monotropein's regulation of macrophage polarization.
  • To elucidate the mechanism of monotropein in treating colitis-associated cancer (CAC).

Main Methods:

  • Molecular docking, Bio-Layer Interferometry (BLI), Cellular Thermal Shift Assay (CESTA), and DNA endonuclease assay (DARTS) were used to identify VDR as a target.
  • Co-culture systems and macrophage polarization models (RAW264.7 cells) analyzed using RT-PCR, immunofluorescence (IF), and Western blot.
  • Azoxymethane (AOM)/DSS-induced CAC mouse models, including VDR knockout animals, were employed to validate therapeutic effects and signaling pathways (JAK/STAT1).

Main Results:

  • Monotropein demonstrated binding to VDR, confirming it as a direct target.
  • Monotropein intervention led to reduced VDR nuclear translocation, increased JAK1/STAT1 signaling, and M1 macrophage polarization.
  • In vivo studies showed that monotropein ameliorated CAC in VDR-dependent manner, correlating with increased JAK1 levels and M1 polarization.

Conclusions:

  • Monotropein effectively inhibits colitis-associated cancer.
  • The mechanism involves VDR-mediated regulation of the JAK1/STAT1 signaling pathway, promoting M1 macrophage polarization.
  • Monotropein represents a promising natural compound for CRC therapy, particularly in colitis-associated settings.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
213
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
152